GCA
SLS icon

Genesee Capital Advisors’s SELLAS Life Sciences SLS Stock Holding History

Genesee Capital Advisors’s Portfolio SLS Stock Details SLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$127K Hold
30,000
– – 0.05% 133
2025
Q4 		$113K Hold
30,000
– – 0.05% 126
2025
Q3 		$48.3K Buy
+30,000
New +$53.4K 0.02% 123

Other funds holding SLS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Jones Financial Companies
Jones Financial Companies Des Peres, Missouri $208B AUM 16.12% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

Genesee Capital Advisors's SLS Position: Q1 2026 in Review

Genesee Capital Advisors held its SELLAS Life Sciences (SLS) position steady in Q1 2026 at 30,000 shares worth $127K. The position accounts for 0.05% of the portfolio, ranked #133.

Genesee Capital Advisors first reported a position in SLS in Q3 2025 and has held it in 3 quarters since. 160 funds tracked by Wall St. Rank hold SLS as of Q1 2026.

  • Genesee Capital Advisors held 30,000 shares of SELLAS Life Sciences worth $127K as of Q1 2026.
  • Genesee Capital Advisors left its SELLAS Life Sciences share count unchanged in Q1 2026.
  • SELLAS Life Sciences made up 0.05% of Genesee Capital Advisors's portfolio in Q1 2026, its #133 holding.
  • Genesee Capital Advisors first reported a position in SELLAS Life Sciences in Q3 2025 and has held it in 3 quarters since.
  • 160 funds tracked by Wall St. Rank held SELLAS Life Sciences as of Q1 2026.

Based on Genesee Capital Advisors's 13F filing for Q1 2026, filed 22 Apr 2026.